AZ oncology head leaves to become Innate Pharma chairman
December 21, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Innate Pharma
French firm Innate Pharma has announced that the current-AstraZeneca head of oncology is joining the company as chairman of the …
Treatment using light and deep-sea bacteria kills cancer cells
December 20, 2016Medical Communications, Research and Development Vascular-targeted photodynamic therapy
A technique called vascular-targeted photodynamic therapy (VTP) has been developed that sent 49% of patients suffering from prostate cancer into …
Japan announces measure to crack down on drug pricing
December 20, 2016Manufacturing and Production, Medical Communications Japan, Shinzo Abe, opdivo
Japan has committed to annual drug price reviews whilst also expanding the scope by which the prices are deemed to …
J&J’s largest India site to finally operate by 2018
December 20, 2016Manufacturing and Production India, Johnson & Johnson
Johnson & Johnson has reportedly announced that its manufacturing plant in Telangana, India, its largest site in the country, is …
AstraZeneca opens £120 million UK manufacturing facility
December 20, 2016Manufacturing and Production AstraZeneca, Macclesfield
AstraZeneca has officially opened a new manufacturing facility for cancer medicines based in Macclesfield, UK. It becomes the second largest …
AZ oncology head leaves to become Innate Pharma chairman
December 19, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Innate Pharma
French firm Innate Pharma has announced that the current-AstraZeneca head of oncology is joining the company as chairman of the …
Ionis achieves successful Phase 3 trial to treat rare diseases
December 19, 2016Manufacturing and Production, Research and Development Akcea, Ionis, rare disease
Ionis Pharmaceutial announced that the results of a Phase 3 trial into its treatment for hypertriglyceridemia met its primary endpoint. …
AZ secures rights from Ionis for first-ever antisense KRAS cancer drug in $165m deal
December 19, 2016Research and Development, Sales and Marketing AstraZeneca, Ionis, KRAS
AstraZeneca has paid a $28 million milestone payment in its partnership with Ionis Pharmaceuticals over the licensing rights to anticancer …
Robert Ross joins Surface Oncology as chief medical officer
December 19, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Surface Oncology, bluebirdbio
Surface Oncology, an immuno-oncology company developing immunotherapies that target the tumour microenvironment, has announced the appointment of Robert Ross as …
Insider interview: NICE discusses its planned ‘fast-track’ appraisal process
December 19, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, UK, approval
Jenniffer Prescott, associate director of planning, operations and topic selection, answers questions on NICE’s recent plans for a ‘fast-track’ appraisal …
FDA orders new label warnings over anaesthetics risk in children
December 19, 2016Research and Development, Sales and Marketing FDA, anaesthetics
The FDA has announced a new Drug Safety Communication for label warnings on general anaesthetic and sedation products because of …
Novartis acquires Ziarco adding to dermatology pipeline
December 19, 2016Sales and Marketing Novartis, Ziarco, eczema, oral
Novartis has announced that it will acquire UK-based Ziarco, to add Ziarco’s lead investigational oral treatment for moderate-to-severe eczema to …
FDA removes black box warning on Pfizer’s anti-smoking medication
December 19, 2016Medical Communications, Sales and Marketing GlaxoSmithKline, Pfizer, anti-smoking, nicotine, smoking
The FDA has decided to remove the “black box” warning upon Pfizer’s anti-smoking drug, Chantix, basing its decision upon the …
Mylan launches $300 generic EpiPen to calm pricing controversy
December 16, 2016Sales and Marketing Mylan, epipen
Mylan has launched a generic alternative to its flagship EpiPen auto-injector, a move to placate the outbreak of industry indignity …
Genentech announces Bill Anderson as new CEO
December 16, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bill Anderson, Genentech, Roche
Genentech, the biotech subsidiary of Roche, has announced that Genentech veteran, Ian Clark, will retire as CEO on 1 January. …
Nurofen maker hit by $6m fine over “misleading conduct”
December 16, 2016Sales and Marketing Nurofen, Reckitt Benckiser
After a case last year levied by the Australian Federal Court over “misleading conduct” concerning the marketing of its branded …
MSD-Gilead patent squabble ends in $2.54 billion verdict
December 16, 2016Medical Communications
A patent lawsuit between Gilead Sciences and MSD, known as Merck in the US, has resulted in MSD being awarded …
Top Ten most popular articles on Pharmafile.com this week
December 16, 2016Medical Communications biggest news, biggest stories, top 10, top 10 stories, top stories, top ten
Christmas is nearly here, but there isn’t much Christmas cheer to be had in the pharmaceutical industry. It’s been a …
Six generics companies hit by 20-state-strong lawsuit
December 16, 2016Medical Communications Heritage, Mylan, Teva
Following hot on the heels of yesterday’s news that a former CEO and president of Heritage Pharmaceuticals had been charged …
Actavis UK overcharged NHS with 12,000% price hike, watchdog says
December 16, 2016Medical Communications, Sales and Marketing Actavis, CMA, NHS
Actavis UK has been accused by the Competition and Markets Authority (CMA) of overcharging the NHS by selling its hydrocortisone …
